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Abstract
The human m opioid receptor gene, OPRM1, produces a multitude of alternatively spliced transcripts encoding full-length or
truncated receptor variants with distinct pharmacological properties. The majority of these transcripts are transcribed from
the main promoter upstream of exon 1, or from alternate promoters associated with exons 11 and 13. Two distinct
transcripts encoding six transmembrane domain (6TM) hMOR receptors, m3 and m3-like, have been reported, both starting
with the first nucleotide in exon 2. However, no mechanism explaining their initiation at exon 2 has been presented. Here
we have used RT-PCR with RNA from human brain tissues to demonstrate that the m3 and m3-like transcripts contain
nucleotide sequences from the intron 1-exon 2 boundary and are transcribed from a novel promoter located upstream of
exon 2. Reporter gene assays confirmed the ability of the novel promoter to drive transcription in human cells, albeit at low
levels. We also report the identification of a ‘‘full-length’’ seven transmembrane domain (7TM) version of m3, hMOR-1A2,
which also contains exon 1, and a novel transcript, hMOR-1Y2, with the potential to encode the previously reported hMOR-
1Y receptor, but with exon Y spliced to exon 4 instead of exon 5 as in hMOR-1Y. Heterologous expression of GFP-tagged
hMOR variants in HEK 293 cells showed that both 6TM receptors were retained in the intracellular compartment and were
unresponsive to exogenous opioid exposure as assessed by their ability to redistribute or affect cellular cAMP production, or
to promote intracellular Ca2+ release. Co-staining with an antibody specific for endoplasmic reticulum (ER) indicated that the
m3-like receptor was retained at the ER after synthesis. 7TM receptors hMOR-1A2 and hMOR-1Y2 resided in the plasma
membrane, and were responsive to opioids. Notably, hMOR-1A2 exhibits novel functional properties in that it did not
internalize in response to the opioid peptide [D-Ala2, N-Me-Phe4, Gly-ol5]enkephalin (DAMGO).
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Introduction
Opioids such as morphine, oxycodone, methadone and fentanyl
are widely used in the clinic to treat severe pain. They all exert
their analgesic effect through binding to the m opioid receptor.
Unfortunately, their use is also associated with serious side-effects,
including sedation, inhibition of gastrointestinal transit, nausea
and vomiting, and respiratory depression which occasionally may
be life-threatening. Clinicians have long observed that different
opioids display different pharmacological properties. This has led
to the idea that they may act through distinct opioid receptor
mechanisms. Evidence for the existence of subtypes of the m opioid
receptor first came from binding studies in mice and rats [1–5],
and was later supported by the identification of a series of
alternatively spliced mRNAs encoding m opioid receptor variants
with structural differences at both their N- and C-terminal ends
[6–9]. Different variants may display different expression patterns
across brain regions [10,11] and also differ in efficacy and
desensitization properties mediated by different opioids [12–14].
However, the function and biological relevance of the splice
variants are as yet poorly understood.
The structure of the human OPRM1 gene is complex. The
number of exons identified from the cloning of OPRM1 transcripts
or prediction of putative exons based on comparative genome
analysis approaches 20, and a similar number of alternatively
spliced hMOR-1 transcripts has been reported. The majority of
these variant transcripts are transcribed from the main promoter
upstream of exon 1 and contain the same exons 1, 2 and 3 as the
classical hMOR-1 [15], followed by alternative exons [16], or an
extended exon 3 [17]. Alternative promoters have been identified
upstream of exon 11 [18] and exon 13 [19], located upstream of
exon 1 and exon 2, respectively. At least three distinct transcripts
produced from these alternative promoters, hMOR-1G1, hMOR-
1G2 [18] and hMOR-1K [19], are predicted to encode receptor
variants with only six transmembrane (TM) domains. Two
additional 6TM hMOR variants have been described; the m3
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receptor, which contains exon 2 and parts of exon 3 [20], and
hMOR-1W, containing exon 2 and the complete sequence of exon
3. hMOR-1W was originally deposited in GenBank in 2003 by our
group (Baar et al., GenBank accession no. AY364890), but was
later published by Cadet et al. [21] and Fricchione et al. [22] as
‘‘m3-like receptor’’.
How the truncated 59 end of the m3 transcript is formed has
remained unclear, as no explanation for its initiation at exon 2 has
been presented. An important clue came from the characterization
of the hMOR-1W transcript, which was shown to contain
sequences from the 39 end of intron 1 joined to exon 2. This
observation led us to suggest that the sequences upstream of exon
2 might harbor a previously unrecognized promoter that could be
employed in transcription of hMOR-1W. Here, we have extended
these studies and show that the transcripts encoding hMOR-1W
(m3-like) and m3 are both transcribed from a novel promoter
upstream of exon 2. We also report the identification of a novel
‘‘full length’’ 7TM version of m3, which contains exon 1 and which
we have termed hMOR-1A2. In addition, a transcript with the
potential to encode the previously reported hMOR-1Y receptor
[6] was identified. In this transcript, which we have termed
hMOR-1Y2, exon Y is joined to downstream exon 4 instead of
exon 5 as found in hMOR-1Y.
We have expressed green fluorescent protein (GFP) tagged
versions of 7TM and 6TM hMOR variants in HEK 293 human
embryonic kidney cells, and studied their subcellular localization
and effect on cellular forskolin-induced cAMP levels after opioid
exposure. In agreement with previous observations, we find that
the 6TM receptors are retained in the intracellular compartment,
whereas 7TM receptors are expressed at the plasma membrane.
Interestingly, the 7TM version of m3, hMOR-1A2, exhibited novel
functional properties in that it did not internalize in response to
[D-Ala2, N-Me-Phe4, Gly-ol5]enkephalin (DAMGO), but still was
able to mediate downstream signaling. Our results extend the
insight into the complex mechanisms regulating m opioid receptor
diversity.
Materials and Methods
RT-PCR
RT-PCRs were carried out on human brain RNAs (Ambion)
isolated from hypothalamus, thalamus, hippocampus, medulla,
and amygdala, and from BE(2)-C and SH-SY5Y neuroblastoma
cell lines (American Type Culture Collection), using the Light-
Cycler RNA Amplification Kit Master SYBR Green I (Roche). All
reactions were performed with 500 ng RNA on a LightCycler
System. The oligonucleotide primers (Eurogentec) used in PCR
are listed in Table 1. Transcripts originating from the novel E2
promoter were amplified from human thalamus using forward
primers from the 39 end of intron 1 (Int1_F2 and nested Int1_a)
along with reverse primers (3C_a and nested 3C_b) from a novel
exon in m3 (here referred to as exon 3C) located 336 bp
downstream of exon 3 (here referred to as exon 3A) (Fig. 1 and
Fig. 2A). The novel hMOR-1Y2 transcript was amplified by a two-
step RT-PCR approach. First, nested RT-PCR was carried out
with forward primers from exon Y (Y_c and nested Y_d) and
reverse primers from exon 4 (4_a and nested 4_b), which showed
that exon Y was directly joined to exon 4. Next, RT-PCR was
performed with forward primers from exon 1 (1_a and nested 1_b)
in combination with a reverse primer from the exon Y – exon 4
junction (Y/4). The novel hMOR-1A2 transcript was amplified
from BE(2)-C cells using forward primers from exon 1 (1_a and
nested 1_b) in combination with reverse primers from exon 3C
(3C_a and nested 3C_b). PCR products were purified using the
QIAquickH PCR Purification Kit, or were recovered from agarose
gel using the QIAquickH Gel Extraction Kit (QIAGEN GmbH),
and sequenced with the appropriate primers. Complete details on
PCR and the cycling conditions used are available on request.
Cloning of the 2 kb region upstream of exon 2
Genomic DNA was used as template in PCR with Int1-BglII-4/
Int1-XmaI-4 primers (Table 1), thereby amplifying a 2.1 kb
fragment of the sequences upstream of exon 2 (Figure S1). The
Table 1. PCR primers.
Primer S/Aa Exon/positionb Sequence
1_a S 1/33975 – 33994 59-GCTTGGAACCCGAAAAGTCT-39
1_b S 1/34002 – 34020 59-CCTGGCTACCTCGCACAGC-39
2_c A 2/84407 – 84432 59-CCATTAGGTAATTCACACTCTGGAAG-39
2_d A 2/84378 – 84400 59-GTACTGGTGGCTAAGGCATCTGC-39
3C_a A 3C/86417 – 86438 59-AATATCTTGCATCCATGACCAC-39
3C_b A 3C/86370 – 86391 59-CTTTAATCACAGAACCAGAGCA-39
4_a A 4/113315 – 113336 59-AAAAGCAGGCACTTTCCTAGAG-39
4_b A 4/113287 – 113307 59-GCCTCCTACACATTCTTGAAG-39
Y_c S Y/88735 – 88755 59-CCAGGGTGTCTGTATTCTGAC-39
Y_d S Y/88758 – 88777 59-CTGTCCACTGAGGCAATTTC-39
Y/4 A Y/4/(88800 – 88818) +
(113183 – 113185)
59-TAGCTTGATAACTGCCAAATCG-39
Int1_a S Int1/84262 – 84283 59-AGCTTACCTATATTTTACACTA-39
Int1_F2 S Int1/84183 – 84203 59-GCCAAGCTGATACTGGAAAAC-39
Int1_BglII-4 A 2/TTAGATC + (84338 – 84360) 59-TTAGATCTGTAGATGTTGGTGGCAGTCTTC-39
Int1_XmaI-4 S Int1/CCTCCCGG + (82248 – 82268) 59-CCTCCCGGGAGAACGGGAAATGAGTGGTT-39
a: S, sense; A, antisense; b: numbering according to GenBank Accession no. NG_021208.
Restriction sites in Int1_BglII-4 and Int1_XmaI-4 primers are underlined.
doi:10.1371/journal.pone.0071024.t001
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purified PCR product was given 39 A-ends using AmpliTaq GoldH
polymerase (Applied Biosystems), purified and then inserted into
the PCR 2.1-TOPO vector (Invitrogen) containing 39 T-
overhangs. The TOPO-vector with insert was cut with KpnI and
BglII, and the insert was then purified and inserted into the KpnI
and BglII sites of pGL3 Basic (Promega). Several colonies were
cultivated, purified, test-cut and one was sequenced and used for
further experiments.
Promoter activity assays
HeLa, SH-SY5Y and BE(2)-C cells were seeded in 48-well
plates in 250 ml medium (30–40% confluency), and the following
day (at about 70% confluency) the cells were transfected with
either 250 ng/well of pGL3 Basic (Promega) or 250 ng/well
pGL3 with the putative promoter region using FuGene HD
(Promega), 3 ml/mg DNA. pRL-TK (Promega) encoding Renilla
luciferase was co-transfected to normalize transfection efficiency
(7.5 ng/well). Luciferase activity was measured 24 hours after
transfection using the Dual Luciferase Reporter Assay System
(Promega). Transfection and luciferase measurements were
performed according to the manufacturer’s instructions.
Cloning of hMOR-1 splice variants
Fluorescence-tagged hMOR-1 variants were generated by
insertion of PCR amplified cDNAs into the HindIII/XhoI sites of
the pcDNA3 vector (Invitrogen) with green fluorescent protein
(GFP) already inserted as a C-terminal epitope tag in-frame with
an XhoI cloning site. The pcDNA3-GFP vector was kindly
provided by Dr. Terje Espevik (Institute of Cancer Research
and Molecular Medicine, Faculty of Medicine, NTNU). The
amplification of hMOR-1 variants for cloning was performed
using purified PCR products from the RT-PCRs as template and
oligonucleotide primers with integrated HindIII/XhoI restriction
sites (Table S1). The antisense primers were designed to either
mutate or omit the normal stop-codon in hMOR-1 variants. The
PCR reaction was performed with PCR AmpliTaq GoldH
polymerase (Applied Biosystems) and all constructs were se-
quenced to verify the correct sequence.
Expression of fluorescence-tagged hMOR-1 variants and
confocal laser scanning microscopy
Live HEK 293 human embryonic kidney cells (American Type
Culture Collection) were seeded on 35 mm glass bottom c-
irradiated tissue culture dishes (MatTek Corp.), and transfected
with hMOR/pcDNA3 constructs after 24 h using the FuGENE 6
transfection reagent (Roche). Cells were observed 48 h post-
transfection using an Axiovert 100-M confocal microscope (Zeiss),
equipped with an LSM 510-META laser-scanning unit and a Zeiss
Plan-Apo 6361.4 numerical aperture oil-immersion objective.
Staining (GFP) was visualized using a 488 nm argon laser line and
the appropriate filters. For cells exposed to opioids, the culture
medium was replaced with phosphate buffered saline (PBS) at
37uC immediately before the addition of either [D-Ala2, N-Me-
Phe4, Gly-ol5]enkephalin (DAMGO) (Sigma), morphine (mor-
phine chloride, Lipomed AG), morphine-6-D-glucuronide (M6G)
(Lipomed AG), [D-penicillamine2,5]-enkephalin (DPDPE) (Sig-
ma), or sterile water as a negative control.
Stably transfected HEK 293 cells expressing the various
hMOR-1 variants were obtained after approximately two weeks
of selection with G418 (500 mg/ml). Clones were selected and
checked by confocal laser scanning microscopy for expression of
GFP-tagged hMOR-1 variants.
Adenylyl cyclase assay
Cell extracts. Adenylyl cyclase activity in living cells was
measured as described by Thakker et al. [23]. Briefly, two days
after seeding, preconfluent stably transfected HEK 293 cells (0.06
– 0.13 mg protein/well) expressing opioid receptors were
incubated in Hank’s balanced salt solution (HBSS, Sigma,
200 ml/well) with 0.5 mM 3-isobutyl-1-methylxanthine (IBMX)
for 5 min at 37uC. After adding HBSS/IBMX with agonist
(10 nM – 10 mM) and/or forskolin (10 mM) to a final volume of
500 ml, the plates were incubated at 37uC for 15 min and then
placed in boiling water for 3 min before storage at 220uC.
cAMP assay. Samples were transferred to Eppendorf tubes,
centrifuged (10,0006g, 4uC, 5 min) and supernatants placed in
new tubes. A competition assay was performed in 24 well plates by
mixing 50 ml supernatant, 0.8 pmol [3H]-cAMP (diluted in
25 mM Tris-HCl, pH 7 with 0.084% BSA and 0.5 mM IBMX),
75 ml 25 mM Tris-HCl, pH 7 and 15 ml adrenal cortex extract
(90 mg). A standard curve was made by using 50 ml of cAMP-
solution instead of sample (0.08–50 pmol). After 1 hour incubation
on ice, the reaction was terminated by adding 50 ml 50%
hydroxyapatite solution and incubating on ice for 6 min. The
wells were filled with ice-cold 10 mM Tris-HCl, pH 7 and the
samples were immediately harvested on standard glass fiber filter
(Packard) on a semi-automatic cell harvester. The filters were
washed 6 times, cut, transferred to counting vials and dried. Five
ml scintillation fluid (ReadyProtein, Beckman Coulter) was added
and the samples were left over night before determining the
radioactivity by liquid scintillation counting.
Immunostaining of transiently transfected cells
Twenty four hours after seeding, HEK 293 cells were
transfected using FuGene HD (Roche) and GFP-tagged hMOR-
1AD (m3-like) (1 mg plasmid DNA/dish). After 48 hours, cells were
washed twice in PBS, fixed in 4% paraformaldehyde for 15 min at
RT, washed twice in PBS, permeabilized and blocked by adding
PBS with 5% FCS, 2.5% BSA and 0.2% saponin for 45 min at
RT. Primary antibody against calnexin (AbCam, ab 13504, an
endoplasmic reticulum marker) was diluted 1:100 in blocking
solution (as above) and added to the cells for 45 min at RT. Cells
were washed three times in PBS and incubated with secondary
antibody (Alexa Fluor 647 goat anti-rabbit, A21244, Invitrogen,
1:1000 in blocking solution) for 30 min at RT, then washed three
times in PBS and stored in PBS at 4uC until examined by confocal
laser scanning microscopy (usually the following day).
Western blots
Total extracts from stably transfected HEK 293 cells expressing
four different 7TM-variants of hMOR-1 were made from 50–80%
confluent cells being scraped and lysed in a buffer containing 8 M
urea, 0.5% Triton-X, 0.1 M DTT, 1x complete protease inhibitor
(Roche) and 5x phosphatase inhibitor cocktails 2 and 3 (Sigma).
After 2630 sec of vortexing, samples were centrifuged (15,7006g,
4uC, 15 min) and supernatants snap-frozen in liquid N2 and stored
at 220uC until gel electrophoresis. Total protein (20–60 mg) was
applied to 12% SDS-PAGE gels. After transfer to PDVF
membranes, an antibody against GFP (AbCam, Ab290, diluted
1:2,000) or hMOR-1 (AbCam, Ab137460, 1:1,000) was added
either on membranes from separate gels or on membranes from
duplicate wells originating from the same gel (membrane cut in
two). Both antibodies were visualized by using a near-infrared
(NIR) (800CW) tagged goat anti-rabbit secondary antibody
(LiCor; 1:10,000) and an Odyssey CLx IR scanner. To correct
for any variance in loading, an antibody against ß-actin (AbCam,
Ab6276, 1:10,000) was added followed by a NIR (680RD) goat
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anti-mouse secondary antibody (LiCor, 1:20,000), and images
from the Odyssey Infrared Imaging System were processed using
the Li-Cor software. Bands with the expected size (around 72 kDa)
being detected by both the GFP antibody and the hMOR-1
antibody, were identified as hMOR-1 splice variants. Results from
four western blots were used for determining the relative
expression levels of the different receptors.
Results
Splice variants hMOR-1AD and m3 are transcribed from a
novel promoter upstream of exon 2
In 2003 Cadet et al. [20] published the nucleotide sequence of
the m3 opiate receptor (GenBank accession no. AY195733). m3 is a
6TM receptor which lacks the first of the seven TM domains
normally present in G-protein coupled receptors (Figure 1). The
study did not, however, provide any information on how the
truncated 59 end of the m3 transcript, starting with the first
nucleotide in exon 2, is formed. Intriguingly, the 59 end of the m3
sequence deposited in GenBank (GenBank accession no.
AY195733) contains a duplication of the ten first nucleotides of
exon 2, which does not conform to the GenBank OPRM1 gene
reference sequence (GenBank accession no. NG021208). To
address the possibility that the OPRM1 gene harbors a previously
unrecognized promoter upstream of exon 2, which could be
employed in transcription of m3, a series of RT-PCRs were carried
out with RNA derived from human thalamus, utilizing forward
primers from the 39 end of intron 1 along with reverse primers
Figure 1. Schematic presentation of OPRM1 gene structure and alternative splicing. Exons and introns are shown by boxes and horizontal
lines, respectively. The approximate sizes of introns (in kb) are indicated. The 59 extension of exon 2 and the new exon 3B are indicated by grey boxes.
The locations of the promoters upstream of exons 11, 1, 13 and 2 are indicated. The transcriptional start sites are indicated by arrows. Putative
translation start and stop codons are indicated by open and filled triangles, respectively. For hMOR-1A, the figure includes the full length sequence of
hMOR-1A (GenBank accession number NM_001008504.2) which has a longer 39 UTR than the originally published sequence. This extended sequence
was confirmed in the present study (data not shown). All references are commented upon elsewhere in the manuscript, with the exception of the
work by Du et al. [32] and Choi et al. [33]. a The full length sequence of hMOR-1AD (m3-like) was deposited in GenBank by Baar et al. in 2003 as ‘‘MOR-
1W’’ (Genbank accession no. AY364890).
doi:10.1371/journal.pone.0071024.g001
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from a novel exon in m3 (here referred to as exon 3C) located
336 bp downstream of exon 3 (here referred to as exon 3A)
(Figure 2, panel A). This resulted in amplification of a 1.4 kb
product containing the sequence of the Int1_a forward primer
followed by the 42 subsequent 39-terminal nucleotides of intron 1,
and exon 2 directly joined to exon 3A (Figure 2, panels B and C).
Moreover, RT-PCRs with primers designed to amplify a region of
intron 1 close to the exon 1 border were consistently negative,
excluding the possibility that the transcript was derived from
incompletely spliced mRNA intermediates. This strongly indicated
that the transcript was produced from a novel promoter upstream
of exon 2 (from now referred to as the E2 promoter). However, the
sequence was distinct from that of m3, as the 336 bp intervening
sequence between exon 3A and exon 3C was retained. The
authenticity of the novel transcript was verified in separate RT-
PCRs with thalamus RNA from a different donor, as well as with
Figure 2. Amplification of the hMOR-1AD splice variant originating from the novel E2 promoter. A. RNA from human thalamus was used
in RT-PCR with forward primers from intron 1 (Int1_F2 and nested Int1_a) and reverse primers from exon 3C (3C_a and nested 3C_b). B. The resulting
PCR product had a size of about 1400 bp, confirming its origin from cDNA and not genomic DNA (a product originating from genomic DNA would
have a predicted size of 2200 bp). C. Sequences flanking the intron1-exon2 border. The intron 1 sequence is indicated in lowercase letters and the
exon 2 sequence in uppercase letters. The forward primers from intron 1 used in RT-PCR are indicated in bold and are underlined. The putative
potential translation start codon (ATG) is indicated in bold.
doi:10.1371/journal.pone.0071024.g002
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RNA obtained from hypothalamus, hippocampus, medulla, and
amygdala (Figure S2, panel A), and from BE(2)-C and SH-SY5Y
neuroblastoma cell lines. We denoted this novel variant hMOR-
1W and the sequence was deposited in GenBank (Genbank
accession no. AY364890). The partial sequence of hMOR-1W was
later published by Cadet et al. [21] and Fricchione et al. [22] and
named ‘‘m3-like receptor’’, reflecting its similarity to the m3
receptor published by Cadet et al. [20]. The deduced reading
frame of hMOR-1W extends 12 nucleotides beyond the normal 39
end splice site in exon 3A, which makes it similar to hMOR-1A in
its C-terminus [17], and we therefore propose that this variant is
renamed hMOR-1AD instead of ‘‘m3-like’’ or as originally named
hMOR-1W.
Although a PCR product compatible with the expected size of
the m3 transcript (approximately 1.1 kb) was co-amplified with
hMOR-1AD (m3-like) from human thalamus using intron 1
primers in combination with exon 3C reverse primers, the band
was very weak and we failed to unambiguously demonstrate that
the product represented m3 (Figure 2, panel B). However, a
transcript identical to m3 was amplified using the same primer sets
and RNA obtained from BE(2)-C neuroblastoma cells (Figure S2,
panel B). This demonstrates that the m3 variant, like hMOR-1AD
(m3-like), can be transcribed from the E2 promoter and is likely to
be expressed at very low levels in human brain.
Identification of a novel 7TM version of m3, and a novel
transcript encoding the previously identified hMOR-1Y
Using forward primers from exon 1 in combination with reverse
primers from exon 3C, we amplified a transcript from BE(2)-C
cells that was identical to m3 in its exon combination, but which
also contained exon 1 (Figure 1). This transcript may therefore
encode a ‘‘full length’’ 7TM version of the m3 receptor. Except for
lacking exon 3B, the structure of this novel transcript is similar to
that of hMOR-1A, and we propose that it is named hMOR-1A2.
The sequence of hMOR-1A2 has been deposited in GenBank
(Genbank accession no. JX914655).
Using RNA from human brain tissues (thalamus, amygdala,
medulla) and BE(2)-C and SH-SY5Y neuroblastoma cells, we also
amplified a novel transcript with the potential to encode the
previously reported hMOR-1Y receptor [6], and which we have
termed hMOR-1Y2. Interestingly, in hMOR-1Y2 exon Y is
joined to downstream exon 4, instead of exon 5 as in the original
hMOR-1Y (Figure 1). This is the only hMOR transcript encoding
a full-length receptor in which exon 4 is joined to an upstream
exon other than exon 3a. The sequence of hMOR-1Y2 was
deposited in GenBank under the accession no. AY364230
(originally deposited as hMOR-1V).
Analysis of the novel E2 promoter by reporter gene
assays
The MatInspector (http://www.genomatix.de/online_help/
help_matinspector/matinspector_help.html) and PATCHTM pub-
lic 1.0, (http://www.gene-regulation.com/cgi-bin/pub/
programs/patch/bin/patch.cgi) programs were employed to
search for putative binding sites for known transcription factors
in a 1 kb region of the 59 flanking sequence of exon 2. Putative
binding sites identified within 250 bp of the exon 2 upstream
sequence are shown in Figure 3 (panel A). No element conforming
to the consensus TATA box was evident. However, several
elements conforming to the initiator element (Inr), which
encompasses the transcription start site and has been shown to
be sufficient to accurately initiate transcription both in vitro and in
vivo [24,25] were predicted within 125 bp of the exon 2 immediate
59 flanking sequence. To test the ability of the 59 flanking sequence
of exon 2 to promote transcription, a chimeric E2-luciferase
plasmid containing 2.1 kb of the 59flanking sequence (Figure S1)
was transiently transfected into SH-SY5Y, BE(2)-C, and HeLa
cells, and tested for its ability to drive the expression of the
luciferase reporter gene. A modest but consistent luciferase
production was evident in all three cell lines, suggesting that the
cloned sequences do contain the proper combination of activating
elements required for transcription (Figure 3, panel B). Luciferase
activity was essentially similar between neuronal-like cells and non-
neuronal cells, suggesting that the promoter in vivo may rely on
additional factors or specific cellular conditions for its maximal
activity.
Expression of fluorescence-tagged hMOR-1 variants in
HEK 293 cells, and exposure to m agonists
Heterologous expression experiments of fluorescence-tagged
hMOR variants were undertaken to analyze their intracellular
distribution and their responsiveness to m-specific agonists.
hMOR-1, hMOR-1A, hMOR-1AD (m3-like), hMOR-1A2, m3
and hMOR-1Y2 were tagged by fusion of GFP to the C-terminal
tail. The receptor variants were transiently expressed in HEK 293
cells and analyzed by confocal laser scanning microscopy.
Transient expression of GFP-tagged hMOR-1, hMOR-1A,
hMOR-1A2 and hMOR-1Y2 revealed that these 7TM receptors
resided largely at the plasma membrane (Figure 4), although for
hMOR-1A2 significant staining could also be seen as intracellular
spots (Figure 4, panels A, B and C, t = 0).
The 6TM hMOR-1AD (m3-like) and m3 variants were mainly
localized intracellularly, either distributed evenly throughout the
intracellular compartment including the nucleus (m3 and the
majority of hMOR-1AD cells), or receptors were excluded from
the nucleus and associated with intracellular structures (some of
the hMOR-1AD cells) (Figure 4, panels A, B and C).
Exposure to 5 mM of the m opioid peptide agonist [D-Ala2, N-
Me-Phe4, Gly-ol5]enkephalin (DAMGO) for 30 min was accom-
panied by a clear reduction in membrane labeling and increased
intracellular accumulation of hMOR-1 and hMOR-1A, indicating
agonist-induced endocytosis (Figure 4, panel A). Internalization
was less evident for hMOR-1Y2 at 5 mM DAMGO, but
increasing the concentration to 10 mM resulted in pronounced
internalization (Figure 4, panel A). In contrast, no detectable
internalization was observed for the novel 7TM hMOR-1A2
variant at 5 mM or 10 mM DAMGO (Figure 4, panel A).
Exposure to 20 mM morphine or M6G failed to promote
detectable internalization of any of the receptors localized at the
plasma membrane (Figure 4, panels B and C, respectively). No
change in localization was observed with hMOR-1AD (m3-like)
and m3 upon exposure to DAMGO, morphine, or M6G (Figure 4,
panels A, B and C). Exposure to the d agonist [D-Ala2, N-Me-
Phe4, Gly-ol5]enkephalin (DPDPE) did not affect receptor
localization for any of the splice variants (data not shown).
hMOR-1AD (m3-like) associates with intracellular
structures resembling endoplasmic reticulum
In a fraction of cells, the hMOR-1AD (m3-like) receptor was
excluded from the nucleus and associated with intracellular
structures (Figure 4, panels A, B and C). Because the intracellular
structures visually resembled endoplasmic reticulum (ER), cells
were fixed in paraformaldehyde and stained with an antibody
specific for ER. As shown in Figure 5, significant overlap was
observed between hMOR-1AD (m3-like) localization and ER-
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staining, strongly suggesting that this truncated receptor variant
may be retained at the ER after synthesis.
Functional characterization of the receptor variants by
measuring cAMP levels
Stably transfected HEK 293 cells expressing GFP-tagged
hMOR variants were used in an assay for measurements of
intracellular cAMP levels in live cells [23]. Binding of ligand to m
opioid receptors usually causes a reduction in adenylyl cyclase
activity via release of the a subunit from the heterotrimeric Gai/o-
protein complex, and thereby reduced intracellular levels of
cAMP. All 7TM variants (hMOR-1, hMOR-1A, hMOR-1A2 and
hMOR-1Y2) were functionally active and lowered forskolin-
induced cAMP levels when exposed to DAMGO, morphine, or
M6G (Table 2), and these effects were counteracted by concom-
itant administration of the opioid antagonist naloxone (data not
shown). The potency (IC50) and efficacy (max inhibition) of the
opioids varied between the different receptor variants. For all
opioids tested, the highest efficacy was obtained with the classical
hMOR-1 receptor. For hMOR-1Y2 the potencies of the opioids
were comparable to those obtained with hMOR-1. For hMOR-
1A2, all tested opioids had lower potencies, especially M6G, as
compared to what was obtained with the other 7TM variants.
None of the 6TM variants (hMOR-1AD and m3) had any
detectable effect on forskolin-induced cAMP levels. The d agonist
DPDPE had detectable effect on cAMP levels in cells expressing
full-length receptors, but significantly less than observed with the m
specific opioids (data not shown).
Discussion
The human OPRM1 gene undergoes extensive alternative
splicing at both its 59 and 39 end, resulting in a multitude of
transcripts which differ in their exon combinations. The majority
of these alternatively spliced transcripts encode 7TM hMOR
variants which are transcribed from the main promoter associated
with exon 1. However, an increasing number of transcripts
encoding short peptide fragments or N-terminally truncated 6TM
receptor variants have been identified, and these transcripts are
produced from alternate promoters located upstream of exons 11
and 13.
Here we present data supporting the existence of yet another
promoter in the OPRM1 gene, which is located upstream of exon 2
and employed in transcription of at least two differentially spliced
6TM variants, hMOR-1AD (m3-like) and m3. Luciferase reporter
gene assays experimentally confirmed the ability of the sequences
upstream of exon 2 to promote transcription in human cells, albeit
at low levels. The sequence contains numerous putative binding
sites for transcription factors, including several elements conform-
ing to the consensus core promoter PyPyANT/APyPy initiator
(Inr) sequence, but the significance of these elements for
Figure 3. Structure and activity of the E2 promoter. A. Schematic presentation of the E2 promoter. Putative transcription factor binding
elements are indicated by triangles. The position of an Alu repeat element is indicated by a horizontal arrow. The promoter sequence was examined
by the MatInspector and PATCHTM public 1.0 programs for potential binding sites for known transcription factors. B. Activity of the E2 promoter
assessed by reporter gene assay. HeLa, SH-SY5Y and BE(2)-C cells were transfected with empty pGL3 Basic vector (Promega) or pGL3 containing the
putative promoter region, as well as the control vector pRL-TK. Luciferase activity was measured using a dual luciferase kit according to the
manufacturer’s instructions (Promega). The measurements were performed in two independent experiments with three to six parallels in each. Each
experiment comprised three different cell lines and showed comparable results. The results from one representative experiment are shown. The
luciferase activity was significantly higher in all cell lines transfected with the novel E2 promoter region as compared to pGL3 Basic vector (p,0.005,
student’s t-test).
doi:10.1371/journal.pone.0071024.g003
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transcription from this promoter is unclear as no detailed
functional characterization of the promoter was carried out. The
low level of transcription measured in reporter gene experiments is
in agreement with the need for nested PCR in order to detect these
truncated transcripts in human brain tissue or in neuroblastoma
cell lines, suggesting that they are expressed at very low levels.
Interestingly, the m3 transcript was present in detectable
amounts only in BE(2)-C cells whereas hMOR-1AD (m3-like)
could be detected in RNA samples from several brain regions.
Both transcripts originate from the E2 promoter, and their only
structural difference is the retention of exon 3B in hMOR-1AD.
Exon 3B is also the only structural difference between hMOR-1A
and hMOR-1A2. It is therefore tempting to speculate that the
ability of the splicing machinery to recognize the splice sites
flanking exon 3B may be important in the control of expression of
Figure 4. Distribution patterns of C-terminally GFP-tagged hMOR-1 variants transiently expressed in HEK 293 cells. HEK 293 cells
were transiently transfected with expression constructs for hMOR-1, hMOR-1A, hMOR-1AD (m3-like), hMOR-1A2, m3 and hMOR-1Y2 as indicated. In
untreated cells (t = 0), hMOR-1, hMOR-1A and hMOR-1Y2 receptors were localized predominantly in the plasma membrane, whereas the novel variant
hMOR-1A2 was observed both in the plasma membrane and in intracellular granula. The truncated splice variants hMOR-1AD (m3-like) and m3 were
retained largely intracellularly, either spread throughout the entire cell (like most cells expressing m3) or associated with intracellular structures and
excluded from the nucleus as for many of the cells expressing hMOR-1AD (m3-like). In cells exposed to DAMGO (A), hMOR-1, hMOR-1A and to some
extent hMOR-1Y2 receptors were observed in numerous intracellular vesicles. No clear effect of DAMGO treatment (5 and 10 mM) was observed with
the novel hMOR-1A2. For the truncated receptors (hMOR-1AD and m3), exposure to DAMGO had no effect on receptor localization. Exposure to
morphine (B) or M6G (C) did not affect the intracellular distribution of receptors. Fields of cells were analyzed by confocal microscopy as described in
Materials and Methods.
doi:10.1371/journal.pone.0071024.g004
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these hMOR variants, and may contribute to a cell- or tissue-
specific expression pattern in human brain.
Although an increasing number of 6TM hMOR variants have
been reported, their functional significance remains largely
unexplored. When overexpressed in HEK 293 cells, hMOR-
1AD (m3-like) and m3 receptors were not expressed at the plasma
membrane but instead accumulated in the intracellular compart-
ment. Co-staining of hMOR-1AD (m3-like) transfected cells with
an antibody specific for endoplasmic reticulum (ER) indicated that
the receptor in a fraction of cells was retained at the ER. However,
intracellular retention does not necessarily imply that the 6TMs
receptors are biologically inactive. Gris and co-workers [26]
showed that the 6TM hMOR-1K variant, despite being retained
intracellularly, was biologically active and led to increased Ca2+
levels as well as increased nitric oxide (NO) release upon morphine
stimulation. Interestingly, unlike hMOR-1, which couples to the
inhibitory Gai/o complex, hMOR-1K couples to the stimulatory
Gas complex and may function to counteract the cellular actions
mediated by 7TM hMOR receptors. However, in our study we
were unable to demonstrate any effect of the truncated m3 and
hMOR-1AD (m3-like) receptors on cellular cAMP production after
exposure to opioid agonists. Similarly, we could not detect any
effect of morphine stimulation on intracellular Ca2+ mobilization
with these truncated variants using a fluorescence-based GFP-
certified calcium assay kit (GFP-Certified FluoForte Calcium
Assay Kit, Enzo Life Sciences Inc.) and morphine exposure
(10mM) for up to 25 min with continuous data recording (data not
shown). It should be noted, however, that Gris et al. used different
cell types, COS1 and BE(2)-C, to demonstrate functionality, and it
is possible that the internalized signaling mechanisms could be
different or more easily detectable in these cell types than in stably
transfected HEK 293 cells. Truncated variants have also been
proposed to bind to and modulate the activity of regular 7TM
receptors. Indeed, in a recent study truncated variants were shown
to be physiologically important through heterodimerization [27].
In that study the 6TM mMOR-1G receptor produced a high-
affinity opioid binding target when co-expressed with the ORL1
receptor, but was inactive when expressed alone. Thus, important
functional roles of truncated MOR-1 variants are beginning to
emerge and call for more thorough investigation into their
function and endogenous partners in the future.
We found that the full-length receptors, hMOR-1, hMOR-1A,
the novel hMOR-1A2, and hMOR-1Y2, accumulated in the
plasma membrane, although hMOR-1A2 showed some degree of
Figure 5. hMOR-1AD is associated with endoplasmic reticulum. Transiently transfected HEK 293 cells expressing GFP-tagged hMOR-1AD (m3-
like) were fixed in paraformaldehyde and stained with an antibody against endoplasmic reticulum. The staining pattern caused by antibody (A) and
the receptor itself (B) demonstrates a high degree of overlap, shown as yellow color in C. This strongly indicates that in cells with this staining
pattern, hMOR-1AD (m3-like) is associated with the endoplasmic reticulum.
doi:10.1371/journal.pone.0071024.g005
Table 2. Inhibition of forskolin-stimulated cAMP accumulation by opioids in hMOR-1 variantsa.
DAMGO Morphine M6G
IC50 (nM) Max. inhib. (%) IC50 (nM) Max. inhib. (%) IC50 (nM) Max. inhib. (%)
hMOR-1 5.862.1 70.865.3 10.562.8 73.565.6 27.3611.2 70.665.2
hMOR-1A2 64.5615.7 63.062.7 89.7625.7 42.962.7 239.9670.1 49.663.7
m3 ND ND ND ND ND ND
hMOR-1A 14.563.1 43.162.3 45.2615.7 49.363.9 16.164.7 48.763.0
hMOR-1AD (m3-like) ND ND ND ND ND ND
hMOR-1Y2 5.162.1 56.169.3 17.366.8 64.261.6 8.163.5 50.560.8
aThe IC50 and maximal inhibition were calculated by nonlinear regression analysis using Prism 4.0, GraphPad Software. Results are means 6 S.E.M. of 3–7 independent
determinations. Maximal inhibition: Maximal inhibition was determined after correcting for different receptor expression levels by western blot analyses (Figure S3).
The expression levels of receptor variants were calculated relative to that of hMOR-1 (which was set to 1). Significant differences in maximal inhibition were observed for
DAMGO (p,0.05), morphine (p,0.01) and M6G (p,0.01). For maximal inhibition by DAMGO, post hoc Tukey analyses showed that hMOR-1 differed from hMOR-1A
(p,0.05). For maximal inhibition by morphine, post hoc Tukey analysis showed that hMOR-1 differed from hMOR-1A2 (p,0.01) and hMOR-1A (p,0.05). For maximal
inhibition by M6G, post hoc Tukey analysis showed that hMOR-1 differed from hMOR-1A2 (p,0.05) and hMOR-1A (p,0.05). IC50: Significant differences of IC50 were
observed for DAMGO (p,0.0001), morphine (p,0.05) and M6G (p,0.05). For DAMGO, post hoc Tukey analyses showed that the IC50 value of hMOR-1 differed from
hMOR-1A2 (p,0.001), and hMOR-1A2 differed also from hMOR-1A (p,0.001) and hMOR-1Y2 (p,0.001). For morphine, post hoc Tukey analyses showed that the IC50
value of hMOR-1 differed from hMOR-1A2 (p,0.05). For M6G, post hoc Tukey analyses showed that the IC50 value of hMOR-1 differed from hMOR-1A2 (p,0.05) and
hMOR-1A2 differed also from hMOR-1A (p,0.05) and hMOR-1Y2 (p,0.05). ND: not determinable.
doi:10.1371/journal.pone.0071024.t002
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intracellular retention in a majority of cells. All these variants share
identical protein structures across the membrane spanning regions,
but differ at the intracellular C-terminus. In accordance with
previous observations with traditional full-length hMOR-1 vari-
ants [28–31], exposure to the opioid peptide DAMGO resulted in
agonist-induced endocytosis of receptors, but notably, not with
hMOR-1A2. This was surprising since the predicted binding
pockets of all four receptors involve identical TM domains. Thus it
appears that the unique intracellular C-terminal amino acid
sequence of hMOR-1A2, which is identical to that of the reported
opioid peptide insensitive m3 receptor, influence the response to
opioid peptides. Importantly, the inability of hMOR-1A2 to
internalize did not compromise its ability to mediate opioid-
dependent inhibition of adenylyl cyclase, as cAMP assays clearly
demonstrated that hMOR-1A2 responds to DAMGO, as well as
to morphine and M6G, although the potencies of these opioids
were much lower for hMOR-1A2 than for the other full-length
receptor variants. Differences in the C-terminus have been shown
to influence both the potency and efficacy of opioids [6]. For
example, in the present study the IC50 values for M6G varied 30-
fold between different full-length receptor variants, M6G being
most potent with hMOR-1Y2 and least potent with hMOR-1A2,
whereas variation in opioid efficacy between variants was less
pronounced.
In summary, we have shown that the OPRM1 gene harbors an
alternative promoter upstream of exon 2, which is utilized to
generate at least two differentially spliced hMOR transcripts, m3
and hMOR-1AD (m3-like). When expressed in HEK 293 cells,
both 6TM receptors were defective in trafficking to the plasma
membrane and did not respond to exogenous opioid stimulation.
We have also identified a full-length version of m3, denoted
hMOR-1A2, which contains exon 1 and which exhibits novel
functional properties in that it does not internalize in response to
DAMGO, but still is able to mediate downstream signaling. The
biological relevance of these hMOR-1 splice variants remains
unknown, and need to be explored in further studies in order to
unravel their potential role in endogenous and exogenous opioid
signaling.
Supporting Information
Figure S1 Cloning of the E2 promoter. A 2.1 kb fragment
of intron 1, immediately upstream of exon 2, was amplified using
the Int-XmaI-4 and Int1-BglII-4 primers indicated, purified and
given 39A ends before subcloning into the PCR 2.1-TOPO vector
(Invitrogen). This vector and pGL3 Basic vector were cut with
KpnI/BglII and the purified 2.1 kb DNA fragment was ligated with
the linearized pGL3 vector (Promega). The resulting vector was
used for measurements of promoter activity in a reporter assay
system measuring luciferase activity.
(PDF)
Figure S2 Amplification and sequencing of transcripts
for hMOR-1AD (m3-like) and m3. A) hMOR-1AD (m3-like) was
amplified by RT-PCR using primers from intron 1 (Int1_F2 and
nested Int_a) along with reverse primers (3C_a and nested 3C_b)
from the novel exon 3C in m3, located 336 bp downstream of exon
3A. RNA from different brain regions as indicated was used as
template in separate reactions. The amplified product correspond-
ing to mMOR-1AD is indicated by an arrow at the left. Sizes (bp)
of relevant bands of the size marker (l cut by PstI) are shown at the
right. B) Co-amplification of hMOR-1AD (m3-like) and m3
transcripts from BE(2)-C cells, using primers from intron 1
(Int1_F2 and nested Int_a) along with reverse primers (3C_a and
nested 3C_b). The upper band (1378 bp) corresponds to hMOR-
1AD (m3-like) whereas the lower band (1042 bp) corresponds to the
m3 transcript. C) Separate amplification of transcripts for hMOR-
1AD (m3-like, lane 1) and m3 (lane 2) using DNA picked from the
bands in panel B as template. These amplified products were
sequenced and verified to represent hMOR-1AD (m3-like) and m3,
respectively. Both transcripts contained the sequence of the Int1_a
primer followed by the 42 subsequent 39-terminal nucleotides of
intron 1 directly linked to exon 2. In hMOR-1AD (m3-like) exon 2
was followed by exon 3A, 3B and 3C, whereas in m3 the 336 bp
exon 3B was spliced out (see panels D–F). D) Sequencing of the
intron1 – exon 2 border of hMOR-1AD (m3-like). The reverse
sequence is shown (red line: exon 2, blue line: intron 1). E) In
hMOR-1AD (m3-like) exon 3A (red) is spliced to the 336 bp exon
3B (blue), followed by exon 3C (yellow). F) In m3 exon 3A (red) is
spliced to exon 3C (yellow).
(DOC)
Figure S3 Expression levels of different splice variants
of hMOR-1 in stably transfected HEK293 cells. GFP-
tagged splice variants were detected in total cell extracts using a
GFP-specific antibody. The identity of the bands was confirmed
by an antibody against human m opioid receptor (data not shown).
Uneven loading was corrected for by relating the signals obtained
with the GFP antibody to signals obtained with an antibody
against ß-actin. The relative levels of expression were calculated
from four separate western blots, loading from 20 to 60 mg of total
protein. The values were calculated relative to the hMOR-1
variant and were found to be as follows: hMOR-1: 1, hMOR-1A2:
0.89, hMOR-1A: 1.35 and hMOR-1Y2: 0.69.
(PDF)
Table S1 PCR primers with integrated restriction sites
for cloning of hMOR-1 variants into the pcDNA3-GFP
vector.
(DOCX)
Acknowledgments
The authors wish to thank members of the ‘‘Pain and Palliation Research
Group’’ at the Faculty of Medicine, NTNU, for critical discussion, Turid
Nilsen for preparing the opioid stock solutions, Trude Teoline Rakva˚g for
contributing to the preparation of stably transfected cell lines, and Ruth
Krokan and Nina Beate Liabakk for assistance with DNA sequencing.
Author Contributions
Conceived and designed the experiments: SA CB TF FS. Performed the
experiments: SA CB TF EAL. Analyzed the data: SA CB TF EAL FS.
Contributed reagents/materials/analysis tools: FS. Wrote the paper: SA
CB FS. Revised the manuscript critically for important intellectual content:
TF EAL.
References
1. Pasternak GW, Snyder SH (1975) Identification of novel high affinity opiate
receptor binding in rat brain. Nature 253: 563–565.
2. Pasternak GW, Childers SR, Snyder SH (1980) Naloxazone, a long-acting
opiate antagonist: effects on analgesia in intact animals and on opiate receptor
binding in vitro. J Pharmacol Exp Ther 214: 455–462.
3. Pasternak GW, Childers SR, Snyder SH (1980) Opiate analgesia: evidence for
mediation by a subpopulation of opiate receptors. Science 208: 514–516.
4. Wolozin BL, Pasternak GW (1981) Classification of multiple morphine and
enkephalin binding sites in the central nervous system. Proc Natl Acad Sci U S A
78: 6181–6185.
5. Hahn EF, Carroll-Buatti M, Pasternak GW (1982) Irreversible opiate agonists
and antagonists: the 14-hydroxydihydromorphinone azines. J Neurosci 2: 572–
576.
A Novel Promoter in the Human OPRM1 Gene
PLOS ONE | www.plosone.org 10 August 2013 | Volume 8 | Issue 8 | e71024
6. Pan L, Xu J, Yu R, Xu MM, Pan YX, et al. (2005) Identification and
characterization of six new alternatively spliced variants of the human mu opioid
receptor gene, Oprm. Neuroscience 133: 209–220.
7. Pasternak DA, Pan L, Xu J, Yu R, Xu MM, et al. (2004) Identification of three
new alternatively spliced variants of the rat mu opioid receptor gene: dissociation
of affinity and efficacy. J Neurochem 91: 881–890.
8. Pan YX, Xu J, Mahurter L, Bolan E, Xu M, et al. (2001) Generation of the mu
opioid receptor (MOR-1) protein by three new splice variants of the Oprm gene.
Proc Natl Acad Sci U S A 98: 14084–14089.
9. Pasternak GW (2004) Multiple opiate receptors: deja vu all over again.
Neuropharmacology 47 Suppl 1: 312–323.
10. Abbadie C, Pan Y, Drake CT, Pasternak GW (2000) Comparative immuno-
histochemical distributions of carboxy terminus epitopes from the mu-opioid
receptor splice variants MOR-1D, MOR-1 and MOR-1C in the mouse and rat
CNS. Neuroscience 100: 141–153.
11. Abbadie C, Pan YX, Pasternak GW (2004) Immunohistochemical study of the
expression of exon11-containing mu opioid receptor variants in mouse brain.
Neuroscience 127: 419–430.
12. Abbadie C, Pasternak GW (2001) Differential in vivo internalization of MOR-1
and MOR-1C by morphine. Neuroreport 12: 3069–3072.
13. Koch T, Schulz S, Pfeiffer M, Klutzny M, Schroder H, et al. (2001) C-terminal
splice variants of the mouse mu-opioid receptor differ in morphine-induced
internalization and receptor resensitization. J Biol Chem 276: 31408–31414.
14. Bolan EA, Pan YX, Pasternak GW (2004) Functional analysis of MOR-1 splice
variants of the mouse mu opioid receptor gene Oprm. Synapse 51: 11–18.
15. Wang JB, Johnson PS, Persico AM, Hawkins AL, Griffin CA, et al. (1994)
Human mu opiate receptor. cDNA and genomic clones, pharmacologic
characterization and chromosomal assignment. FEBS Lett 338: 217–222.
16. Pan YX, Xu J, Mahurter L, Xu M, Gilbert AK, et al. (2003) Identification and
characterization of two new human mu opioid receptor splice variants, hMOR-
1O and hMOR-1X. Biochem Biophys Res Commun 301: 1057–1061.
17. Bare LA, Mansson E, Yang D (1994) Expression of two variants of the human
mu opioid receptor mRNA in SK-N-SH cells and human brain. FEBS Lett 354:
213–216.
18. Xu J, Xu M, Hurd YL, Pasternak GW, Pan YX (2009) Isolation and
characterization of new exon 11-associated N-terminal splice variants of the
human mu opioid receptor gene. J Neurochem 108: 962–972.
19. Shabalina SA, Zaykin DV, Gris P, Ogurtsov AY, Gauthier J, et al. (2009)
Expansion of the human mu-opioid receptor gene architecture: novel functional
variants. Hum Mol Genet 18: 1037–1051.
20. Cadet P, Mantione KJ, Stefano GB (2003) Molecular identification and
functional expression of mu 3, a novel alternatively spliced variant of the human
mu opiate receptor gene. J Immunol 170: 5118–5123.
21. Cadet P, Mantione KJ, Zhu W, Kream RM, Sheehan M, et al. (2007) A
functionally coupled mu3-like opiate receptor/nitric oxide regulatory pathway in
human multi-lineage progenitor cells. J Immunol 179: 5839–5844.
22. Fricchione G, Zhu W, Cadet P, Mantione KJ, Bromfield E, et al. (2008)
Identification of endogenous morphine and a mu3-like opiate alkaloid receptor
in human brain tissue taken from a patient with intractable complex partial
epilepsy. Med Sci Monit 14: CS45–49.
23. Thakker DR, Ozsoy HZ, Standifer KM (2003) Assessing opioid regulation of
adenylyl cyclase activity in intact cells. Methods Mol Med 84: 29–37.
24. Smale ST, Baltimore D (1989) The ‘‘initiator’’ as a transcription control
element. Cell 57: 103–113.
25. Javahery R, Khachi A, Lo K, Zenzie-Gregory B, Smale ST (1994) DNA
sequence requirements for transcriptional initiator activity in mammalian cells.
Mol Cell Biol 14: 116–127.
26. Gris P, Gauthier J, Cheng P, Gibson DG, Gris D, et al. (2010) A novel
alternatively spliced isoform of the mu-opioid receptor: functional antagonism.
Mol Pain 6: 33.
27. Majumdar S, Grinnell S, Le Rouzic V, Burgman M, Polikar L, et al. (2011)
Truncated G protein-coupled mu opioid receptor MOR-1 splice variants are
targets for highly potent opioid analgesics lacking side effects. Proc Natl Acad
Sci U S A 108: 19778–19783.
28. Arden JR, Segredo V, Wang Z, Lameh J, Sadee W (1995) Phosphorylation and
agonist-specific intracellular trafficking of an epitope-tagged mu-opioid receptor
expressed in HEK 293 cells. J Neurochem 65: 1636–1645.
29. Keith DE, Murray SR, Zaki PA, Chu PC, Lissin DV, et al. (1996) Morphine
activates opioid receptors without causing their rapid internalization. J Biol
Chem 271: 19021–19024.
30. Burford NT, Tolbert LM, Sadee W (1998) Specific G protein activation and mu-
opioid receptor internalization caused by morphine, DAMGO and endomor-
phin I. Eur J Pharmacol 342: 123–126.
31. Chen LE, Gao C, Chen J, Xu XJ, Zhou DH, et al. (2003) Internalization and
recycling of human mu opioid receptors expressed in Sf9 insect cells. Life Sci 73:
115–128.
32. Du YL, Elliot K, Pan YX, Pasternak GW, Inturrisi CE (1997) A splice variant of
the mu opioid receptor is present in human SHSY-5Y cells. Soc Neurosci 23:
1206.
33. Choi HS, Kim CS, Hwang CK, Song KY, Wang W, et al. (2006) The opioid
ligand binding of human mu-opioid receptor is modulated by novel splice
variants of the receptor. Biochem Biophys Res Commun 343: 1132–1140.
A Novel Promoter in the Human OPRM1 Gene
PLOS ONE | www.plosone.org 11 August 2013 | Volume 8 | Issue 8 | e71024
